Sector News

Mylan, Lupin, others now in the mix for $1.1B Bayer derm buy

September 27, 2016
Life sciences

The list of drugmakers reportedly eying Bayer’s up-for-sale dermatology unit is growing even longer.

Mylan, New Jersey’s Leo Pharma and India’s Lupin, Cadila Healthcare and Torrent Pharmaceuticals are all weighing offers for the unit, which could bring in more than $1.1 billion for the German drugmaker as it looks to fund the $66 billion Monsanto acquisition it recently agreed to, Bloomberg reports.

Previous reports listed Nestle’s Galderma, Spain’s Almirall, India’s Sun Pharma, Teva, Allergan and Perrigo as potential suitors on the pharma side, while private equity firms such as KKR and Bain Capital have featured in the rumors, too.

The companies may not have much more time to decide whether to officially jump into the fray, though. Bids may be due as soon as this week, sources told the news service.

Both Mylan and Leo have made recent deals in the dermatology space. Bayer’s portolio–which includes eczema therapy Desonate and rosacea treatment Finacea–could bolster the €675 million worth of skincare assets Leo Pharma agreed last year to to buy from Japan’s Astellas, or those Mylan in May announced it would be buying with a $1 billion deal for Renaissance Acquisition Holdings.

Meanwhile, dermatology may not be the only divestment Bayer’s looking into. It’s also considering a potential divestment of its radiology business, which could fetch more than $3 billion, Bloomberg’s sources say.

Earlier this year, Sanford Bernstein analyst Jeremy Redenius suggested that a long-buzzed-about animal health sale could help Bayer drum up funds for the Monsanto buy, too.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).